
Rote-Hand-Brief – Direct Safety Communication to Healthcare Professionals
Contents
What is a Rote-Hand-Brief?
A Rote-Hand-Brief informs healthcare professionals about important new medicine-safety findings and necessary actions in Germany. Pharmaceutical companies distribute it in agreement with the responsible authorities. The corresponding international term is Direct Healthcare Professional Communication (DHPC).
The red hand is a recognizable signal for safety information. A letter may address new contraindications, necessary monitoring or changes to use. Not every product update or adverse-reaction report is a Rote-Hand-Brief.
How does it differ from other information?
The summary of product characteristics and package leaflet describe approved conditions of use. A DHPC draws attention to a significant safety change and its practical implications. Approved Blue Hand educational materials provide a different, often continuing risk-minimization resource.
These forms should not be mixed with promotional campaigns. Safety information must be deliverable through the appropriate channels independently of marketing consent. The particular distribution needs coordination with responsible functions and the agreed communication plan.
Which information matters most?
Recipients should quickly understand the medicine and use affected, what has changed and what action is required. Date, sender and access to further information or the authoritative document version also matter.
Summaries must retain the qualifications relevant to action. A linked letter should be clearly identified by active substance, date and safety issue. This helps avoid confusion with an older or unrelated communication.
What should companies consider when providing it?
Pharmacovigilance, Medical, Regulatory Affairs and communication teams need coordinated processes. Existing materials, training and relevant website pages require assessment against the safety change. Published copies and downloads need version management.
The BfArM collection covers products within its responsibilities; other products may fall particularly within the Paul-Ehrlich-Institut's remit. Accessing a safety letter does not prove that the recommended action has been implemented.
Conclusion: Prioritize clear safety information and implementation
The Rote-Hand-Brief serves risk communication. Actionable instructions, a current document version and reliable delivery to intended recipients are essential. Success should be assessed against its safety purpose rather than reach or brand impact.

